TAKEDA PHARMACEUTICAL CO LTD 13D and 13G filings for Xilio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2024-07-31 07:46 am Unchanged |
2024-07-31 | 13G | Xilio Therapeutics, Inc. XLO |
TAKEDA PHARMACEUTICAL CO LTD | 1,475,121 4.000% |
0 (Unchanged) |
Filing |
2022-01-14 06:07 am Purchase |
2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
TAKEDA PHARMACEUTICAL CO LTD | 1,475,121 5.370% |
1,475,121![]() (New Position) |
Filing |